Tri Chemical Laboratories (4369) Q3 2025 earnings summary

Executive summary

• Net sales for the nine months ended October 31, 2024, rose 59.5% year-over-year to ¥13,105 million, with operating profit up 156.4% to ¥3,502 million and profit attributable to owners of parent up 74.6% to ¥3,226 million.

• Comprehensive income increased 57.3% year-over-year to ¥3,202 million.

Financial highlights

• Gross profit for the nine months was ¥5,472 million, up from ¥2,952 million year-over-year.

• Ordinary profit reached ¥4,351 million, up 78.4% year-over-year.

• Basic earnings per share increased to ¥99.29 from ¥56.88 in the prior year period.

• Total assets grew to ¥38,214 million as of October 31, 2024, from ¥31,864 million at the previous fiscal year-end.

• Net cash provided by operating activities was ¥3,639 million, with cash and cash equivalents at period-end of ¥10,952 million.

Outlook and guidance

• Full-year net sales forecast is ¥17,000 million, up 51.2% year-over-year.

• Operating profit is projected at ¥3,900 million (up 100.2%), and profit attributable to owners of parent at ¥4,260 million (up 72.4%).

• Basic earnings per share for the full year is forecast at ¥131.09.